Histogen | Evaluate

Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.

Among developers that arrived on the market via reverse mergers, big success stories are hard to find.

January 29, 2020

Investors in Conatus, and especially those in Newlink, should question how valuations of the groups' reversing acquirers have been calculated.

Evaluate